Bio-Path Inc. (BPTH)
Company Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.
The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors.
Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Country | United States |
| IPO Date | Mar 4, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Peter H. Nielsen MBA |
Contact Details
Address: 4710 Bellaire Boulevard Bellaire, Texas United States | |
| Website | https://www.biopathholdings.com |
Stock Details
| Ticker Symbol | BPTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133818 |
| CUSIP Number | 09057N300 |
| ISIN Number | US09057N3008 |
| Employer ID | 87-0652870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter H. Nielsen MBA | Co-Founder, Chairman of the Board, Chief Executive Officer, President, Chief Financial Officer & Treasurer |
| Anthony Price MBA | Senior Vice President of Finance, Accounting & Administration |
| Douglas P. Morris | Co-Founder, Director of Investor Relations, Secretary & Director |
| Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D. | Senior Vice President of Research, Development & Clinical Design |
| Michael Hickey M.B.A. | Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | S-1/A | [Amend] Filing |
| Jan 21, 2025 | S-1 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |